论文部分内容阅读
目的 通过乳腺癌组织中EPB41L4A-AS2的表达,评价其临床病理特征与乳腺癌患者预后之间的关系。方法 利用癌症基因组Meta分析、TCGA和GEO数据集,评价EPB41L4A-AS2的表达量与乳腺癌的临床组织特征之间的关系。利用Western blot实验,在乳腺癌细胞水平验证EPB41L4A-AS2与凋亡通路的关联性。结果 在Meta分析、TCGA和基因表达库(GEO)数据集的结果中发现,乳腺癌组织中EPB41L4A-AS2低表达,并且与不良的临床病理特征正相关。而在乳腺癌细胞系上的实验验证了EPB41L4A-AS2与细胞经典凋亡通路相关联。在GEO中进行荟萃分析的预后研究中,发现EPB41L4A-AS2的高表达与良好的疾病预后有关。结论 EPB41L4A-AS2抑制了肿瘤的形成,对乳腺癌的临床预后分析有较高价值。
Objective To evaluate the relationship between clinicopathological features and the prognosis of breast cancer patients by the expression of EPB41L4A-AS2 in breast cancer. Methods The relationship between the expression level of EPB41L4A-AS2 and the clinicopathological features of breast cancer was evaluated using cancer genome meta-analysis, TCGA and GEO data sets. The correlation between EPB41L4A-AS2 and apoptosis pathway was verified by Western blot in breast cancer cells. Results In the results of Meta-analysis, TCGA and Gene Expression Library (GEO) datasets, it was found that EPB41L4A-AS2 was overexpressed in breast cancer tissues and positively correlated with poor clinical pathological features. However, experiments on breast cancer cell lines confirmed that EPB41L4A-AS2 is associated with the classical apoptotic pathway of cells. In a meta-analysis of prognostic studies in GEO, high expression of EPB41L4A-AS2 was found to be associated with a good prognosis of the disease. Conclusion EPB41L4A-AS2 inhibits tumor formation and has high value in clinical prognosis analysis of breast cancer.